Avidin

Executive Summary

Avidin is a Hungarian biotechnology company founded in 1990 and headquartered in Budapest. The company operates in drug discovery and molecular diagnostics, focusing on developing novel therapeutics for cancer and neurodegenerative diseases, as well as in-vitro diagnostic tests for infectious diseases. Leveraging expertise in genomics, screening, and single-cell analysis, Avidin advances its pipeline through a combination of internal research and service offerings. Currently at a pre-clinical stage, the company is privately held with no disclosed funding or valuation. Despite a long history, the company has not yet advanced to clinical trials, indicating a potentially conservative or under-resourced development approach. However, its diagnostics business may provide near-term revenue opportunities, while its therapeutic pipeline remains in early discovery. The company's position in Central Europe offers cost advantages but limited visibility on major partnerships or significant milestones. Overall, Avidin represents a high-risk, early-stage opportunity with potential upside if its lead programs achieve pre-clinical validation or strategic partnerships.

Upcoming Catalysts (preview)

• Q4 2026Completion of lead optimization for oncology candidate15% success
• Q3 2026Launch of new infectious disease diagnostic test40% success
• Q1 2027Announcement of strategic partnership for neurodegenerative program20% success